because they do not have to be given for as long a period of time. “The cost of goods for us to manufacture one of these cell therapy infusions is $15,000, which is less than 3 months of antibody therapy. Right now, patients are often getting antibodies for their lifespan. If you have a self-replicating cell that can continue to make antibodies, the cells may actually in the end be more cost-effective,” Dr. June said.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
National Cancer Policy Forum, Institute of Medicine "
6 Financial Challenges ."
Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary . Washington, DC: The National Academies Press,
Please select a format: